aTYR PHARMA (ATYR) Return on Sales (2019 - 2026)

aTYR PHARMA's (ATYR) quarterly Return on Sales came in at 4.17% in Q1 2026, up 5.15% on a QoQ basis from 4.4% in Q4 2025.

aTYR PHARMA (ATYR) Return on Sales (2019 - 2026) Analysis & Trends

aTYR PHARMA (ATYR) has 7 years of Return on Sales data on file, last reported at 4.17% in Q1 2026.

Quarterly Return on Sales changed N/A year-over-year to 4.17% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 4.17% (changed N/A YoY) and the FY2025 annual result came in at 11.57%, down 339.0% from the prior year.
Return on Sales advanced to 4.17% in Q1 2026, from 4.4% in the prior quarter.
In the past five years, Return on Sales ranged from a high of 0.01% in Q4 2022 to a low of 4.4% in Q4 2025.
A 5-year average of 1.67% and a median of 1.18% in 2024 frame the typical range for Return on Sales.
Annual changes were most pronounced in 2024 — Return on Sales tumbled 296 bps — and 2025, when it surged 199 bps.
Tracing ATYR's Return on Sales over 5 years: stood at 0.01% in 2022, then plunged by 27251 bps to 2.11% in 2023, then sank by 66 bps to 3.49% in 2024, then declined by 26 bps to 4.4% in 2025, then increased by 5 bps to 4.17% in 2026.
The last three Return on Sales figures came in at 4.17% (Q1 2026), 4.4% (Q4 2025), and 1.51% (Q3 2025), per Business Quant data.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	ROS (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	0.00%
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	0.00%
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	0.00%
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	-0.05%
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	0.00%
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	0.00%
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	0.00%
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	0.00%
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	0.00%
10	aTYR PHARMA	49.54 Mn	-7.87 Mn	-	-

Download Data